Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q8NHH9

UPID:
ATLA2_HUMAN

ALTERNATIVE NAMES:
ADP-ribosylation factor-like protein 6-interacting protein 2

ALTERNATIVE UPACC:
Q8NHH9; B7Z1X2; B7Z7X8; Q4ZG30; Q7Z630; Q8NHH8; Q9H5M7

BACKGROUND:
The protein Atlastin-2, alternatively named ADP-ribosylation factor-like protein 6-interacting protein 2, is instrumental in endoplasmic reticulum tubular network biogenesis. It functions by tethering membranes via GTPase activity, forming trans-homooligomers, and facilitating the homotypic fusion of endoplasmic reticulum membranes, as evidenced by multiple studies (PubMed:18270207, PubMed:19665976, PubMed:27619977).

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Atlastin-2 offers a promising avenue for developing therapeutic strategies. Given its critical role in the structural and functional maintenance of the endoplasmic reticulum, targeting Atlastin-2 could provide novel treatments for conditions stemming from endoplasmic reticulum abnormalities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.